Amgen shares fall after the pelacarsen result and a BMO downgrade

Amgen/Olpasiran

Amgen stock dropped in premarket trading as investors weighed what Novartis's failed Lp(a) outcomes trial means for olpasiran, alongside an analyst downgrade. Investors now wait for OCEAN(a)-Outcomes to show whether olpasiran's deeper Lp(a) cut prevents heart events.

• Shares fell 4.7% to USD 416.88 premarket on 8 Sep 2026.
• BMO Capital cut Amgen to Market Perform, citing a 34% year-to-date rise and patent-expiry concerns.
• Olpasiran and pelacarsen both target Lp(a) but use different RNA mechanisms.